Region-specific alterations in the concentrations of catecholamines and indoleamines in the brains of young and old F344 rats after L-deprenyl treatment

Brain Research Bulletin

Volumn 48, Issue 5, 1999, Pages 513-520

  ThyagaRajan, Srinivasan ^a,b   Stevens, Suzanne Y ^a   Felten, David L ^a,b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

Author keywords

Aging; Dopamine; Monoamine oxidase; Norepinephrine; Selegiline; Serotonin

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; SELEGILINE;

AGING; ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CATECHOLAMINE BRAIN LEVEL; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; NORADRENALIN BRAIN LEVEL; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL;

AGE FACTORS; ANIMALS; BODY WEIGHT; BRAIN CHEMISTRY; CATECHOLAMINES; CORPUS STRIATUM; HYPOTHALAMUS; INDOLES; MALE; MONOAMINE OXIDASE INHIBITORS; NUCLEUS ACCUMBENS; RATS; RATS, INBRED F344; SELEGILINE; SUBSTANTIA NIGRA;

EID: 0033559702     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(99)00030-1     Document Type: Article

References (38)

1. Bellinger, D. L.; Felten, S. Y.; Ackerman, K. D.; Lorton, D.; Madden, K. S.; Felten, D. L. Noradrenergic sympathetic innervation of lymphoid organs during development, aging, and in autoimmune disease. In: Amenta, F., ed. Aging of the autonomic nervous system, Boca Raton, FL; CRC Press; 1993:243-284.
2. Benedetti, M. S.; Keane, P. E. Differential changes in monoamine oxidase A and B activity in the aging rat brain. J. Neurochem. 35: 1026-1032; 1980.
3. Birkmayer, W.; Knoll, J.; Riederer, P.; Youdim, M. B. H. (-)Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod. Probl. Pharmacopsychiatry 19:170-176; 1983.
4. Brandeis, R.; Sapir, M.; Kapon, Y.; Borelli, G.; Cadel, S.; Valsecchi, B. Improvement of cognitive function by MAO-B inhibitor 1-deprenyl in aged rats. Pharmacol. Biochem. Behav. 39:297-304; 1991.
5. de la Cruz, C. P.; Revilla, E.; Steffen, V.; Rodriguez-Gomez, J. A.; Cano, J.; Machado, A. Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl. Br. J. Pharmacol. 117: 1756-1760; 1996.
6. Demarest, K. T.; Moore, K. E. Lack of high affinity transport system for dopamine in the median eminence and posterior pituitary. Brain Res. 171:545-551; 1979.
7. Demarest, K. T.; Moore, K. E. Comparisons of dopamine synthesis regulation in the terminals of nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons. J. Neural Transm. 46:263-277; 1979.
8. Felner, A. E.; Waldmeier, P. C. Cumulative effects of irreversible MAO inhibitors in vivo. Biochem. Pharmacol. 28:995-1002; 1979.
9. Gudelsky, G. A.; Metzer, H. Y. Function of tuberoinfundibular dopa mine neurons in pargyline- and reserpine-treated rats. Neuroendocrinology 38:51-55; 1984.
10. Hall, D. W.; Logan, B. W.; Parsons, G. H. Further studies on the inhibition of monoamine oxidase by M and B 9302 (clorgyline) I. Substrate specificity in various mammalian species. Biochem. Pharmacol. 18:1447-1454; 1969.
11. Heinonen, E. H.; Antilla, M. I.; Lammintausta, R. A. S. Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites. Clin. Pharmacol. Ther. 56:742-749; 1994.
12. Jahng, J. W.; Houpt, T. A.; Wessel, T. C.; Chen, K.; Shih, J. C.; Joh, T. H. Localization of monoamine oxidase A and B mRNA in the rat brain by in situ hybridization. Synapse 25:30-36; 1997.
13. Johnston, J. P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17:1285-1297; 1968.
14. Jossan, S. S.; Gillberg, P.-G.; Karlsson, I.; Gottfries, C. G.; Oreland, L. Visualization of brain monoamine oxidase B (MAO B) in dementia of Alzheimer's type by means of large cryosection autoradiography: a pilot study. J. Neural Transm. 32(suppl.):61-65; 1990.
15. Knoll, J. Deprenyl (Selegiline): The history of its development and pharmaceutical action. Acta Neurol. Scand. 95(suppl.):57-80; 1983.
16. Knoll, J. The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mech. Ageing Dev. 46:237-262; 1988.
17. Knoll, J.; Dallo, J.; Yen, T. T. Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl. Life Sci. 45:525-531; 1989.
18. Lai, J. C. K.; Leung, T. K. C.; Guest, J. F.; Lim, L.; Davison, A. N. The monoamine oxidase inhibitors clorgyline and L-deprenyl also affect the uptake of dopamine, noradrenaline, and serotonin by rat brain synaptosomal preparations. Biochem. Pharmacol. 29:2763-2767; 1980.
19. Li, X.-M.; Juorio, A. V.; Paterson, I. A.; Zhu, M. Y.; Boulton, A. A. Specific irreversible monoamine oxidase B inhibitors stimulate gene expression of aromatic L-amino acid decarboxylase in PC12 cells. J. Neurochem. 59:2324-2327; 1992.
20. MohanKumar, P. S.; Quadri, S. K. Deprenyl stimulates the release of norepinephrine from the medial basal hypothalamus in vitro. 9th International Congress of Endocrinology, Nice, France; 1992:555.
21. Owen, F.; Bourne, R. C. The heterogeneity of monoamine oxidase in rat brain mitochondria. Biochem. Pharmacol. 26:289-292; 1977.
22. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328:176-180; 1993.
23. Riederer, P.; Jellinger, K. Neurochemical insights into monoamine oxidase inhibitors with special reference to deprenyl (selegiline). Acta Neurol. Scand. 95(suppl.):43-55; 1983.
24. Rodriguez-Gomez, J. A.; Venero, J. L.; Vizuete, M. L.; Cano, J.; Machado, A. Deprenyl induces the tyrosine hydorxylase enzyme in the rat dopaminergic nigrostriatal system. Mol. Brain Res. 46:31-38; 1997.
25. Schneider, L. S.; Pollock, V. E.; Zemensky, M. F.; Gleason, R. P.; Palmer, R.; Sloane, R. B. A pilot study of low dose of L-deprenyl in Alzheimer's disease. J. Geriatr. Psychiatr. Neurol. 4:143-148; 1991.
26. Simpson, L. L. Evidence that deprenyl, a type B monoamine oxidase inhibitor is an indirectly acting sympathomimetic amine. Biochem. Pharmacol. 27:1591-1595; 1978.
27. Student, A. K.; Edwards, D. J. Subcellular localization of types A and B monoamine oxidase in rat brain. Biochem. Pharmacol. 26:2337-2342; 1977.
28. Tariot, P. N.; Sunderland, T.; Weingartner, H.; Murphy, D. L.; Welkowitz, J. A.; Thompson, K.; Cohen, R. M. Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology 91:489-495; 1987.
29. ThyagaRajan S.; Quadri, S. K. Deprenyl stimulates the release of catecholamines and 5-hydroxyindoleacetic acid from the medial basal hypothalamus in vivo. 74th Annual Meeting of the Endocrine Society, San Antonio, TX; 1992:431.
30. ThyagaRajan, S.; Meites, J.; Quadri, S. K. Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decreases the incidence of mammary and pituitary tumors in old acyclic rats. Endocrinology 136: 1103-1110; 1995.
31. ThyagaRajan, S.; Madden, K. S.; Kalvass, J. C.; Dimitrova, S.; Felten, S. Y.; Felten, D. L. L-deprenyl-induced increase in IL-2 and NK cell activity accompanies restoration of noradrenergic nerve fibers in the spleens of old F344 rats. J. Neuroimmunol. 92:9-21; 1998.
32. Tipton, K. F. Enzymology of monoamine oxidase. Cell Biochem. Function 4:79-87; 1986.
33. Turkish, S.; Yu, P. H.; Greenshaw, A. J. Monoamine oxidase-B inhibition: A comparison of in vivo and ex vivo measures of reversible effects. J. Neural Transm. 74:141-148; 1988.
34. Urwyler, S.; Von Wartburg, J.-P. Studies on the subcellular localization of monoamine oxidase types A and B and its importance for the deamination of dopamine in the rat brain. Biochem. Pharmacol. 29: 3067-3073; 1980.
35. Waldmeier, P. C.; Delini-Stula, A.; Maitre, L. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn-Schmiedebergs Arch. Pharmacol. 292:9-14; 1976.
36. Waldmeier, P. C.; Felner, A. E. Deprenyl: Loss of selectivity for inhibition of B-type MAO after repeated treatment. Biochem. Pharmacol. 28:801-802; 1979.
37. Westfall, T. C.; Naes, L.; Paul, C. Relative potency of dopamine agonists on autoreceptor function in various brain regions of the rat. J. Pharmacol. Exp. Ther. 224:199-205; 1983.
38. Yang, H.-Y. T.; Neff, N. H. The monoamine oxidases of brain; Selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J. Pharmacol. Exp. Ther. 189:733-740; 1974.